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Background: Diabetic cardiomyopathy is characterized by systolic and early diastolic ventricular dysfunction. In the
metabolic syndrome (MS), ventricular stiffness is additionally increased in a later stage. It is unknown whether this is
related to intrinsic cardiomyocyte dysfunction, extrinsic factors influencing cardiomyocyte contractility and/or cardiac
function, or a combination of both. A first aim was to study cardiomyocyte contractility and Ca2+ handling in vitro in a
mouse model of MS. A second aim was to investigate whether in vivo hypocaloric diet or ACE-inhibition (ACE-I)
improved cardiomyocyte contractility in vitro, contractile reserve and Ca2+ handling.
Methods: This study was performed in LDL-receptor (LDLR−/−) and leptin-deficient (ob/ob), double knock-out mice
(DKO), featuring obesity, type II diabetes, atherogenic dyslipidemia and hypertension. Single knock-out LDLR−/−, ob/ob
and wild type mice were used as controls. Cellular contractility, Ca2+ handling and their response to in vivo treatment
with diet or ACE-I were studied in isolated cardiomyocytes at baseline, during β-adrenergic stimulation or increased
extracellular Ca2+, using field stimulation and patch-clamp.
Results: In untreated conditions, prolongation of contraction-relaxation cycle and altered Ca2+ handling are observed
in MS. Response to increased extracellular Ca2+ and β-adrenergic stimulation is impaired and could not be rescued by
weight loss. ACE-I restored impaired response to β-adrenergic stimulation in MS, but not the decreased response to
increased extracellular Ca2+.
Conclusions: Cardiomyocyte contractility and β-adrenergic response are impaired in MS, due to alterations in cellular
Ca2+ handling. ACE-I, but not weight loss, is able to restore cardiomyocyte response to β-adrenergic stimulation in MS.
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ACE-inhibitionBackground
The metabolic syndrome (MS) is characterized by the
co-occurrence of at least three of the following features:
abdominal obesity, hypertension, dyslipidemia, insulin
resistance ± glucose intolerance, pro-inflammatory and
pro-thrombotic status. The prevalence of MS and diabetes
mellitus type II (DMII) is increasing. Affected patients
are at higher risk of developing cardiovascular compli-
cations, caused by diabetic, combined with ischemic,* Correspondence: Paul.herijgers@med.kuleuven.be
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distribution, and reproduction in any mediumcardiomyopathy and angiopathy. The existence of a
primary diabetic cardiomyopathy has been shown in
diabetic animal models [1]. The co-occurrence of hyper-
tension and dyslipidemia in DMII aggravates cardiovas-
cular dysfunction in vivo [2].
MS-associated cardiomyopathy can be distinguished
in vivo from diabetic cardiomyopathy by impaired late
diastolic function, lower end-diastolic volume, decreased
cardiac output and concentric hypertrophy [2].
Cardiac function is determined by intrinsic cardio-
myocyte function, but also influenced by myoarchitecture,
composition and structure of the extracellular matrix, by
preload and afterload. It is unclear whether the in vivotral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cardiomyocyte dysfunction and/or extrinsic factors influ-
encing cardiomyocyte or cardiac contractility. No studies
are available on isolated cardiomyocyte contractility in
MS-mice.
Calcium plays a key role in excitation-contraction
coupling in cardiomyocyte contractility. Myocyte con-
traction is determined by entry of Ca2+ via L-type cal-
cium channels that triggers release of Ca2+ from the
sarcoplasmatic reticulum (SR) via ryanodine receptors
(RyR) and activation of myofilaments. Relaxation occurs
with sequestration of Ca2+ from the cytosol to the SR by
SR Ca2+ ATP-ase (SERCA2a) and extrusion of Ca2+ out
of the cell by the sodium-calcium exchanger (NCX).
Alterations in Ca2+ cycling in DMII and failing hearts
have been extensively studied [3-5]. We have shown
previously in ventricular homogenates of MS-mice that
phosphorylation of phospholamban (PLB) is decreased
and associated with an increased SERCA2a-expression
[2]. Although these data provide insights into contributing
mechanisms to contractile dysfunction in vivo, changes
in intrinsic properties of cardiomyocytes have not been
studied in MS-mice.
Diet and ACE-I are the golden standard in the treat-
ment of DMII and MS. Their beneficial effects on
cardiovascular complications have been established in
clinical and experimental settings. Diet has proven to
reduce cardiac hypertrophy, to ameliorate diastolic func-
tion, insulin resistance and blood pressure in MS [6-8].
ACE-I improves endothelial function, reverses cardiovas-
cular remodeling effects and has an anti-atherosclerotic
effect [9-11]. It remains unclear to what extent these
observations can be explained by intrinsic cardiomyocyte
dysfunction and/or extrinsic factors influencing cardio-
myocyte or cardiac contractility.
The first aim of our study was to phenotype cardio-
myocyte contractility and Ca2+ handling in DKO to gain
further insight in the contributing mechanisms to cardiac
failure in MS. A second goal was to study the effect of
in vivo treatment with diet or ACE-I on cardiomyocyte
contractility and Ca2+ handling.
Methods
Animals
Experiments were conducted in homozygous LDL-re-
ceptor (LDLR−/−) and leptin-deficient (ob/ob), double
knock-out mice (DKO) of either gender at 12, 18 and 24
weeks with C57BL/6J (WT), LDLR−/− and ob/ob as
reference data. Mice were backcrossed for at least 10
generations into C57BL/6J, exhibiting 98.4% C57BL/6J
background. Heterozygous ob/+ and C57BL/6J were
purchased from Jackson Laboratory (Bar Harbor, ME,
USA). Homozygous ob/ob and DKO mice were generated
as described previously [12]. The investigation conformsto the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No.85-23, revised 1996) and approved by the
institutional review board.
Metabolic analysis
Blood was taken by tail bleeding into EDTA-tubes, after
24 hours fasting.
Serum glucose was measured with a glucometer
(Menarini Diagnostics). Plasma was acquired by centrifu-
gation. Triglycerides (TGL), total cholesterol (Chol), high-
density lipoprotein (HDL) and low-density lipoprotein
levels (LDL) were determined with a diagnostic reagent
kit (Roche).
Food restriction
Mice were fed standard chow containing 9% fat (Ssniff,
Germany). Food intake of free-fed DKO and LDLR−/−
mice was respectively 5.7 and 2.5 g/day [13]. Food intake
of diet-restricted DKO and ob/ob was reduced to the daily
food intake of LDLR−/− (2.5 g/day) with free access to
water, between 12 and 24 weeks of age.
ACE-inhibition
Captopril (10 mg/kg) [14] was daily injected intraperito-
neally (from 12 till 24 weeks of age) in ob/ob and DKO.
Cell isolation
Ventricular myocytes from 24 weeks-old mice were iso-
lated as described previously [15]. Briefly, mice were
heparinized (5000 IU/ml) and euthanized with pento-
barbital (50 mg/ml, ip). The heart was excised and
weighted. Single left ventricular myocytes were obtained
by enzymatic dissociation through retrograde perfusion
of the aorta, using collagenase A (0.4-0.5 mg/ml, Roche
Diagnostics, Germany) and protease (type XIV 0.08
mg/ml, Sigma, USA). Cells were used within 5 hours
after isolation.
Measurement of cellular contraction, [Ca2+]i transients
(CaT) and SR Ca2+ content
Unloaded cell shortening was measured by video-edge
detection (Crescent, Salt Lake City, USA) during field
stimulation (Myopacer Cell Stimulator, IonOptix, Milton,
USA). Cells were stimulated at 1, 2 and 4 Hz to determine
a shortening-frequency relationship. Cell contraction is
expressed as fractional cell shortening (FCS) i.e. cell
length change normalized to resting cell length. Kinetics
of contraction were evaluated as time-to-peak contraction
(TTP) and relaxation as time to 50% relaxation (RT50),
starting from peak contraction.
CaT were measured in cardiomyocytes, preloaded with
Fluo-3 AM (10 μM for 20 minutes), using perforated
patch-clamp and data were calibrated as previously
Nevelsteen et al. BMC Cardiovascular Disorders 2013, 13:51 Page 3 of 9
http://www.biomedcentral.com/1471-2261/13/51described [16]. SR Ca2+ load was estimated as the peak
CaT obtained during 7s fast application of 10 mM caffeine.
NCX function was evaluated as the decline of the caffeine
evoked CaT. In a subset of cells, ruptured patch-clamp
was used to asses L-type Ca2+ current (ICaL). The voltage-
clamp protocol consisted of a pre-step from −70 to −50
mV to inactivate INaL, followed by depolarizing voltage
steps from −40 up to +60 mV; duration of the step
was 200 ms. Pipette solution was Cs-aspartate based
with 10 mM NaCl.
The study on Ca2+ handling was performed in
untreated and food-restricted DKO using WT as
control.Response to Ca2+ challenge and β-adrenergic stimulation
Contractile reserve was studied at 1 Hz by using iso-
proterenol (50 nM) (non-selective β-adrenoreceptor
agonist) or by increasing extracellular Ca2+ (from 1 toTable 1 Metabolic and phenotypic evolution
WT Ob/ob
At 12 w Untreated Food restriction
Body Weight(g) 21.1±1.0 49.5±0.6* 49.8±0.9*
Glycemia(mg/dL) 56±2.0 159.3±18.5* 166±13.7*
Total Chol(mg/dL) 104±25 129±6£ 131±6
Triglycerides(mg/dL) 115±15 53±2*£ 53±2*
HDL(mg/dL) 68±11 106±5*£ 107±5*
LDL(mg/dL) 16±11 13±2 14±2
WT Ob/ob
At 18 w Untreated Food restriction
Body Weight(g) 22.1±1.3 56.6±0.9*£ 37.1±1.1*+
Glycemia(mg/dL) 72±4.5 134±18.9 176±19.9*
Total Chol(mg/dL) 80±7 154±13* 77±6+
Triglycerides(mg/dL) 75±6 81±2 74±5
HDL(mg/dL) 62±6 123±9*£ 67±7+
LDL(mg/dL) 4±2 15±4* /
WT Ob/ob
At 24 w Untreated Food restriction
Body Weight(g) 27.1±0.9 64.5±0.9* 34.0±2.3*+
Heart Weight(mg) 164.4±9.6 196.1±9.3* 136.4±2.8*+
HW/BW ratio(mg/g) 6.2±0.5 3.1±0.1* 4.3±0.3*+
Glycemia(mg/dL) 71±4,5 166±11.8* 142±12.1*
Total Chol(mg/dL) 93±17 139±10 74±8
Triglycerides(mg/dL) 68±9 68±3 69±5
HDL(mg/dL) 73±9 97±6 66±8
LDL(mg/dL) 8±7 29±5 /
This table shows the metabolic and phenotypic evolution from 12 till 24 weeks of a
food-restricted ob/ob (N =32), food-restricted DKO (N =19), ob/ob treated with ACE-
* denotes p < 0.05 vs. WT, + p < 0.05 vs. untreated ob/ob and £ p < 0.05 vs. untreate
high-density lipoprotein, LDL low-density lipoprotein and / = No data available.1.8 mM). FCS was measured at steady-state and
expressed as percent increase in FCS.
All experiments were performed at 35°C.Data management and statistical analysis
Analysis of data was performed using Clampfit 8.2 (Axon
Instruments, Scotland), Origin (Originlab, USA) and
Ionwizard (IonOptix, USA). Data are expressed as mean ±
standard error of the mean (SEM).‘N’ denotes number of
animals and ‘n’ denotes number of cells. Differences be-
tween groups were analyzed for statistical significance by
ANOVA with a Fisher post-hoc test, using Statistica 7.1
(StatSoft, USA). p < 0.05 was considered significant.Results
We did not see any difference between WTand LDLR−/−.
Therefore, results obtained from LDLR−/− will not be
reported. Additionally, ACE-I did not alter in vivoDKO
ACE-I Untreated Food restriction ACE-I
49.0±0.3* 48.8±0.7* 51.2±0.6* 45.2±1.6*
155±14.5* 155±10.2* 156±8.8* 160±12.9*
116±6 977±45*+ 958±77* 735±90*£
69±3* 585±66*+ 618±75* 455±69*
90±4* 232±5*+ 112±10*£ 137±11*£
12±3 / / 308±228*
DKO
ACE-I Untreated Food restriction ACE-I
54.0±0.4* 49.8±3.4*+ 37.3±0.7*£ 53.9±1.8*
119±9.1 142±13.4 158±19.8* 191±24.3*
140±10* 579±145*+ 794±59* 527±63*
70±2 334±80*+ 331±38* 171±19£
112±7* 100±6*+ 201±18*£ 159±11*£
16±3* 277±100*+ 519±35*£ 334±50*
DKO
ACE-I Untreated Food restriction ACE-I
65.8±1.3* 61.2±1.7* 35.9±1.3*£ 61.8±1.0*
178.7±4.0 184.2±10.0 132.7±3.0*£ 161.2±4.0£
2.7±0.1* 3.1±0.1* 3.8±0.2* 2.6±0.1*
84±5.0+ 141±28.6* 153±18.2* 124±8.7*
145±10 576±78*+ 816±74*£ 634±55*
76±4 210±30*+ 301±60* 202±21*
100±2 183±15*+ 232±21*£ 192±4*
34±8 351±66*+ 432±24* 402±49*
ge of WT (N =13), untreated ob/ob (N =10), untreated DKO (N =13),
I (N =14) and DKO treated with ACE-I (N =16).
d DKO; HW heart weight, BW body weight, Total Chol total cholesterol, HDL
Nevelsteen et al. BMC Cardiovascular Disorders 2013, 13:51 Page 4 of 9
http://www.biomedcentral.com/1471-2261/13/51cardiac contractility in WT [17]. Therefore, cardiomyocyte
contractility of WTafter ACE-I has not been studied.
Phenotypic and metabolic evolution (Table 1)
Phenotypic and metabolic features of MS in untreated DKO
At 24 weeks, DKO and ob/ob body weight (BW) was
significantly higher, compared to WT. Similarly, heart
weight (HW) was higher in DKO and ob/ob, resulting
in a significantly lower heart weight over body weight
ratio (HW/BW ratio), compared to WT. DKO and
ob/ob showed a significant hyperglycemia. Addition-
ally, DKO showed a marked atherogenic dyslipidemia
(high levels of Chol, TGL and LDL), compared to
WT and ob/ob.
Significant weight loss with hypocaloric diet
Diet resulted in significant weight loss in DKO and
ob/ob, associated with significantly lower HW. HW/Figure 1 Cell contraction at baseline in WT, ob/ob and DKO at 24 we
WT, ob/ob and DKO (A), unloaded cell shortening (B), TTP (C) and RT50 (D
(n = 25). * denotes p < 0.05 vs. WT, + p < 0.05 vs. untreated ob/ob and £ p<BW ratio was significantly increased in ob/ob after
diet, compared to untreated ob/ob. Less marked ef-
fect of diet on HW/BW ratio was obtained in DKO.
Hyperglycemia was reduced in ob/ob, whereas hyper-
glycemia and atherogenic dyslipidemia were still
present in DKO after diet. The same was observed
at 12 and 18 weeks.Significantly lower heart weight in DKO after in vivo
treatment with ACE-I
ACE-I resulted in a significantly lower HW in DKO,
but unchanged BW, leading to a small decrease in
HW/BW ratio. Neither HW, nor BW were influenced
by ACE-I in ob/ob. Fasting glycemia was no longer
increased in ob/ob whereas hyperglycemia and
atherogenic dyslipidemia remained present in DKO
after ACE-I.eks. Representative example of unloaded cell shortening at 1 Hz in
) at 1 Hz stimulation frequency in WT (n = 44), ob/ob (n = 24) and DKO
0.05 vs. untreated DKO.
Figure 2 Myocyte contraction under stress in the different
genotypes and effect of treatment at 24 weeks. Effect of 50 nM
isoproterenol on cell shortening amplitude (A) and effect of increased
extracellular Ca2+ (1.8 mM) on cell shortening amplitude (B) in the
different groups. * denotes p < 0.05 vs. WT, + p < 0.05 vs. untreated
ob/ob and £ p < 0.05 vs. untreated DKO.
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Prolongation of excitation-contraction cycle in
untreated DKO
A similar, negative shortening-frequency relationship
was observed in DKO, WT and ob/ob (data not shown).
Cell width was significantly larger in DKO (13.4±0.3
μm) and ob/ob (13.5±0.3 μm) compared to WT (9.5±0.2
μm), with similar resting cell length in all groups (data
not shown). Figure 1A is a representative example of
unloaded cardiomyocyte shortening at 1 Hz in WT, ob/
ob and DKO with similar FCS in all genotypes (Figure 1B).
TTP was significantly longer in DKO and ob/ob than in
WT (Figure 1C). RT50 was significantly longer in DKO,
than in WT and ob/ob (Figure 1D). Regarding contractile
reserve, cell shortening increased in all genotypes upon
isoproterenol application or increased extracellular Ca2+.
However, the relative increase was in both situations
smaller in ob/ob and further reduced in DKO, compared
to WT (Figure 2).
Normalization of contraction cycle in DKO after diet
Diet improved contraction and relaxation in DKO only;
TTP and RT50 were significantly shorter after diet in
DKO, compared to untreated DKO (Figure 1C and D).
However, the response to isoproterenol or increased
Ca2+ remained impaired in DKO, as well as in ob/ob
(Figure 2).
Partial rescue of contractile reserve after in vivo treatment
with ACE-I
DKO developed a significantly faster relaxation after
ACE-I, but TTP was unaffected (Figure 1C and D). Unlike
diet, ACE-I leads to a significant increase in β-adrenergic
response in DKO, compared to untreated DKO. Response
to extracellular Ca2+ was not improved. In ob/ob, there
was a clear tendency towards improvement of the re-
sponse to isoproterenol or increased Ca2+, without
reaching significance (Figure 2).
Calcium handling in isolated cardiomyocytes
Impaired Ca2+ handling in untreated DKO
Figure 3A shows a representative example of CaT
obtained during short depolarizing pulses at 1 Hz in WT
and DKO. Diastolic Ca2+ at 0.5, 1, 2 and 4 Hz was not
different between WT and DKO (data not shown). At 1
and 4 Hz, CaT amplitude in DKO was significantly smaller
(Figure 3B), associated with slower kinetics (longer TTP
and slower relaxation) (Figure 3C and D), compared to
WT. SR Ca2+ content, evaluated as the peak CaT evoked
during caffeine application was not different between
DKO and WT (Figure 4A). Decline of the caffeine evoked
CaT was prolonged in DKO compared to WT (Figure 4B).
ICaL density and voltage-dependence were similar for WT
and DKO (Figure 4C).Improved Ca2+ handling in DKO after diet
Diet resulted in a significant increase in CaT amplitude
in DKO with faster kinetics, in particular TTP (Figure 3).
SR Ca2+ content remained comparable between the
groups after diet (Figure 4A). Ca2+ decline during caffeine
application was improved with diet (Figure 4B). ICaL
remained unchanged after diet (Figure 4C).Discussion
In this study, we determined cardiomyocyte contractility
and Ca2+ handling in isolated cardiomyocytes in a mouse
model of MS. The first new finding of our study is
functional characterization of single cardiomyocytes in
a mouse model of MS. At the cellular level, MS is char-
acterized by slower kinetics of contraction and relax-
ation. DKO mice show a significantly longer TTP and
RT50, indicating prolongation of contraction-relaxation
cycle. The second finding is that contractile reserve is
impaired in isolated cardiomyocytes from MS-mice.
ACE-I, but not weight reduction, can restore the response
to β-adrenergic stimulation. However, the attenuated
response to extracellular Ca2+ is not improved by the
aforementioned treatments.
Both findings are a hallmark of failing myocardium.
Furthermore, these cellular defects are in parallel with
previous in vivo studies in our laboratory and with clinical
studies [1,2,6-8].
Figure 3 CaT properties in WT, DKO and DKO undergoing hypocaloric diet. (A) Representative example of CaT recording during short
depolarizing pulses at 1 Hz in WT, DKO and DKO after diet. CaT amplitude (B) time to peak (C) and RT50 (D) in WT ( n = 14), DKO (n = 21) and DKO
diet (n = 18). * denotes p < 0.05 vs. WT and £ p < 0.05 vs. untreated DKO.
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In vivo, diastolic dysfunction in MS is characterized by
an early and late component. The late component is due
to enhanced myocardial fibrosis, resulting in decreased
end-diastolic volume [2]. The early component is charac-
terized by impaired active relaxation. Early relaxation
occurs when Ca2+ is removed from the cytoplasm into the
SR via SERCA2a and out of the cell by the NCX, and re-
flects dissociation of Ca2+ from contractile myofilaments.
SERCA2a is a membrane protein that catalyzes ATP-
dependent transport of Ca2+ from the cytosol into the SR
and regulated by PLB. In 24 weeks-old DKO, preserved
PLB/SERCA2a ratio is associated with decreased phos-
phorylation of PLB, resulting in decreased activity of
SERCA2a [2]. NCX is considered as the second most im-
portant mechanism for removing Ca2+ from the cytosol.
Hattori et al. showed impaired NCX function in type I
DM (DMI), due to decreased protein expression, playing
an important role in altered Ca2+ handling [18]. In
DKO, we report a significantly longer RT50 forcardiomyocyte contraction and CaT, mainly related to
SERCA2a and PLB. Ca2+ decline after administration of
caffeine is significantly prolonged in DKO, indicating
altered NCX function. Although, we did not look at
changes in NCX expression, it is likely that both mech-
anisms (decreased phosphorylation of PLB and altered
NCX function) contribute to impaired relaxation in
MS. Finally, unaltered levels of resting calcium indicate
that the “pump-leak balance” is unchanged, as previ-
ously described in DMI [4].
After in vivo treatment with diet and ACE-I, RT50 is
comparable with WT. Diet also improved Ca2+ handling
in DKO. These findings are consistent with previous
in vivo studies, showing diet to improve cardiac function
and insulin sensitivity in MS-mice [5-7]. The beneficial
effect of ACE-I is largely due to improved endothelial
function, its anti-atherosclerotic and anti-remodeling
effects [9-11,19]. All together, our data provide evi-
dence for contribution of intrinsic cellular mechanisms,
in recovering diastolic function after diet and ACE-I,
Figure 4 SR Ca2+ content, NCX function and ICaL in WT, DKO
and DKO undergoing hypocaloric diet. (A) Averaged data on SR
Ca2+ content, measured as the peak caffeine-evoked CaT in WT
(n=12), DKO (n =12) and DKO diet (n=12). (B) Pooled data on NCX
function, estimated as the decline of the caffeine-induced CaT in WT
(n=12), DKO (n=12) and DKO diet (n=12). (C) L-type Ca2+ current
density (ICaL) expressed as a function of voltage in WT (n=11), DKO
(n=8) and DKO diet (n=10). * denotes p<0.05 vs WT and £ p<0.05 vs.
untreated DKO.
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ventricular-vascular stiffening, reduced subendothelial
lipid deposition and increased endothelium-dependent
relaxation) [6-11,19].
Systolic dysfunction
In vivo, MS is characterized by systolic dysfunction,
reflected by reduced cardiac output [2]. Cellular contrac-
tion starts when Ca2+ enters the cell via L-type Ca2+channels and thereby activating RyR that will lead to
further Ca2+ release from the SR. Ca2+ will in turn activate
myofilaments, inducing contraction. This process is
known as calcium-induced-calcium-release, playing a
key role in cellular contraction.
In DMI, L-type Ca2+ channel activity is unchanged,
but RyR protein levels are decreased [4]. DKO have a
significantly smaller CaT amplitude and a significantly
larger TTP. These data, taken together with lower
protein levels of RyR, suggest RyR to be likely responsible
for the slow Ca2+ release from the SR, since no changes in
L-type Ca2+ current were found. Our data in DKO show
that FCS is preserved despite a decrease in CaT amplitude.
This might be explained by an increase in myofilament
Ca2+ sensitivity. However, we did not asses myofilament
sensitivity in DKO and experiments on contractility and
Ca2+ handling were conducted in different cell groups. It
is also unclear how DM affects myofilament sensitivity.
Whereas some studies suggested that DM is associated
with decreased myofilament sensitivity, others indicate
the opposite [20,21]. On the other hand, it is important
to notice that slowed relaxation, as found in DKO, is
also a feature of increased myofilament sensitivity. Diet
and ACE-I did not influence TTP of cellular contraction.
In contrast, diet did improve kinetics of CaT in DKO,
in particular TTP, suggesting that diet might influence
expression or activity of RyR or myofilament sensitivity.
Decreased β-responsiveness
Depressed β-responsiveness is a hallmark of heart fail-
ure. The mechanisms underlying impaired β-responsive-
ness have been extensively studied. It remains unclear
whether this attenuated response is attributable to de-
creased expression of β-receptors, to distal transduction
pathways defects and/or to impaired Ca2+ handling. Pre-
vious studies showed a decreased β-receptor expression/
activity; however, more recent studies demonstrate
impaired β-inotropy, without changes in β-adrenoceptor
expression/activity [22,23]. Minhas et al. showed im-
paired β-adrenergic response in ob/ob, due to altered
PKA-activity and reversible by leptin repletion [24]. We
confirmed impaired contractile reserve in ob/ob and
found a more pronounced impairment in DKO. Although
we did not study β-receptor expression/activity or distal
signaling pathways, it is likely that altered PKA-activity
might also play a role in DKO, due to the same lack of
leptin in these mice. Another possible contributor is
reduced insulin sensitivity. As shown, DKO are hyper-
glycemic, hyperinsulinemic and insulin resistant. Insulin
might contribute to cardiomyocyte β-responsiveness
because of cross-talk between β-adrenergic and insulin
receptors, mediated via Akt-pathway [25]. Consistent
with this cross-talk, overexpression of insulin growth
factor improves β-response in DMI [26]. On the other
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alter PKA-mediated activity and phosphorylation [27].
Whether insulin resistance contributes to β-inotropic
hyporesponsiveness remains controversial. Yonemochi
et al. showed in cultured ventricular neonatal rat myocytes
that captopril enhances β-adrenergic responsiveness by
inducing β-adrenergic receptor upregulation, mediated
via activation of bradykinin B2-receptors and PKC [28].
Our study gives more insight in the pathophysiological
mechanisms contributing to heart failure in MS and
provides potential therapeutic targets in prevention and
treatment of cardiovascular complications in MS.
Limitations of our study
A limitation of our study is leptin deficiency in our mice.
In humans, obesity is associated with hyperleptinemia.
Long-term hyperleptinemia results in leptin resistance.
Leptin resistance and interrupted leptin signaling were
reported in cardiomyocytes under hyperleptinemic con-
ditions, making hyperleptinemia comparable to leptin
deficiency regarding signaling pathways of leptin [29].
A possible contributor to our results after diet is the
extreme weight loss that our mice experienced. It was
remarkable that heart weight in DKO and ob/ob after
diet was lower, compared to WT. Extreme weight loss
eg. starvation, has detrimental effects on cardiac perform-
ance [30]. These adverse starvation-effects strongly em-
phasize the need for tightly controlled weight reduction.
In the present study, we did not study the effect of
ACE-I or β-adrenergic stimulation on Ca2+ handling,
neither did we investigate molecular changes in calcium
handling or contractile proteins. These remain interest-
ing issues for future research.
Conclusion
In vivo cardiac dysfunction, as seen in MS and shown
previously in our laboratory and in humans, can at least
partially be explained by alterations of intrinsic pro-
perties of cardiomyocytes [1,2,8,9]. We have shown that
cardiomyocyte contractility and β-adrenergic response
are impaired in MS, due to alterations in Ca2+ handling.
ACE-I, but not weight loss, can restore impaired
cardiomyocyte response to β-adrenergic stimulation in
MS-mice.
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